Table 9.
Substance | Batch | N | LC (%) | Concentration (mg/kg) | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Median | Mean | P95b | Maximum | ||||||||
LB | UB | LB | UB | LB | UB | LB | UB | ||||
Morphine | 1st | 775 | 11 | 10.0 | 10.0 | 38.2 | 38.6 | 202 | 202 | 630 | 630 |
2nd | 1,164 | 2 | 13.6 | 13.6 | 57.8 | 57.8 | 253 | 253 | 596 | 596 | |
Codeine | 1st | 557 | 32 | 1.40 | 1.40 | 4.95 | 5.23 | 14.9 | 14.9 | 827 | 827 |
2nd | 962 | 25 | 1.40 | 1.40 | 5.93 | 6.15 | 28.0 | 28.0 | 298 | 298 | |
Thebaine | 1st | 356 | 19 | 2.00 | 2.00 | 15.7 | 15.8 | 101 | 101 | 783 | 783 |
2nd | 869 | 31 | 1.20 | 1.20 | 12.4 | 12.6 | 64.0 | 64.0 | 455 | 455 | |
Oripavine | 1st | 43 | 42 | 4.00 | 4.00 | 20.8 | 21.3 | n.a. | n.a. | 233 | 233 |
2nd | 41 | 63 | 0 | 0.100 | 1.78 | 1.85 | n.a. | n.a. | 27.5 | 27.5 | |
Noscapine | 1st | 330 | 69 | 0 | 1.00 | 1.02 | 1.70 | 4.20 | 4.20 | 39.2 | 39.2 |
2nd | 782 | 60 | 0 | 1.00 | 1.84 | 2.34 | 6.30 | 6.30 | 86.9 | 86.9 | |
Papaverine | 1st | 102 | 81 | 0 | 0.750 | 0.090 | 0.590 | 0.400 | 1.00 | 1.79 | 1.79 |
2nd | 304 | 71 | 0 | 0.100 | 0.150 | 0.250 | 1.15 | 1.15 | 3.20 | 3.20 | |
Narceine | 2nd | 41 | 54 | 0 | 0.100 | 0.230 | 0.290 | n.a. | n.a. | 1.61 | 1.61 |
Acetylcodeine | 2nd | 43 | 100 | 0 | 0.100 | 0 | 0.100 | n.a. | n.a. | 0 | 0.100 |
N: number of samples; LB: lower bound; LC: left‐censored; n.r.: not applicable; P95: 95th percentile; UB: upper bound.
Discrepancies in the descriptive statistics of the 1st batch of data compared to the 2011 opinion are due to the way of handling left‐censored data. In the present report, analytical results showing a concentration below the reported limit of quantification (LOQ) were considered as LC irrespectively of whether or not it was specified by the data provider as below the LOQ.
The 95th percentile with less than 60 observations may not be statistically robust (EFSA, 2011b) and is therefore not calculated.